Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Covid-19 save search
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 3.71%
H: 3.45%
C: 2.3%
covid-19 bemnifosbuvir antiviral pharmaceuticals global trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.1285 490.75% 32K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.09%
C: -5.9%
covid-19 drug antiviral trial
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: 0.89%
H: 3.42%
C: -0.88%
covid-19 update trial
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 2.77%
H: 2.69%
C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
AIMD | $1.03 1.92% 21K
|
Manufacturing
|
| O: 11.65%
H: 0.0%
C: -6.09%
covid-19 fda drug resolve trial response
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
Published: 2024-01-08 (Crawled : 21:00) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 1.61%
H: 11.43%
C: 9.52%
covid-19 hepatitis positive pharmaceuticals virus trial milestone study
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
Published: 2023-12-12 (Crawled : 14:00) - globenewswire.com
NURO | News | $4.28 17.26% 14.72% 250K
|
Health Technology
|
| O: -2.86%
H: 3.24%
C: 2.65%
covid-19 quell trial pilot results
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K
|
Health Technology
|
| O: 6.63%
H: 12.99%
C: 6.78%
rhb-107 covid-19 funding study phase 2
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
Published: 2023-10-30 (Crawled : 13:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 0.0%
H: 2.02%
C: -1.42%
covid-19 vaccine expansion trial phase 2
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published: 2023-10-04 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.48%
H: 0.2%
C: -0.33%
rna-1083 covid-19 vaccine positive influenza
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Published: 2023-09-19 (Crawled : 14:00) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.18%
H: 5.8%
C: 2.92%
covid-19 study
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
COEP | $0.34 -3.13% -3.24% 190K
|
|
| O: 10.2%
H: 0.0%
C: -5.56%
dvx201 covid-19 update infection risk trials aml therapeutics
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
Published: 2023-09-13 (Crawled : 13:00) - biospace.com/
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 1.04%
H: 2.23%
C: 1.98%
covid-19 trial
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
covid-19 treatment trial
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Initial primary endpoint data anticipated in late 2023 or early Q1 2024
Published: 2023-09-11 (Crawled : 19:00) - biospace.com/
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 1.69%
H: 7.22%
C: 1.67%
vyd222 covid-19 trial
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
Published: 2023-09-11 (Crawled : 13:30) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 3.12%
H: 0.0%
C: -5.53%
covid-19 vaccine trial phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.